Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online:2228
  • Home
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2016  |  Volume : 30  |  Issue : 3  |  Page : 198-203

A prospective, double-blind dose-ranging study of intrathecal nalbuphine in the lower abdominal and lower limb surgeries


Department of Anaesthesiology, Midnapore Medical College, Midnapore, West Bengal, India

Correspondence Address:
Suman Chattopadhyay
BC 103, Salt Lake, Kolkata - 700 064, West Bengal
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0970-5333.198060

Rights and Permissions

Background: Nalbuphine is a synthetic opioid with mixed agonist-antagonist action, used as an adjuvant with intrathecal bupivacaine to prolong postoperative analgesia. However, only a few studies so far have quantified the optimal intrathecal nalbuphine dose. Our aim was to compare the relative effectiveness of three doses of intrathecal nalbuphine to determine the optimum dose which prolonged analgesia with minimal side effects. Settings and Design: This was a prospective, randomized, double-blind study. Subjects and Methods: Eighty American Society of Anesthesiologists I and II patients undergoing elective lower abdominal and lower limb surgeries under subarachnoid block were randomly allocated to four groups (A, B, C, and D of twenty patients each) to receive 0.5 ml normal saline or 0.8, 1.2, and 1.6 mg nalbuphine added to 0.5% hyperbaric bupivacaine 15 mg. The onset of sensory and motor blockade, two-segment regression time of sensory blockade, duration of motor blockade, duration of analgesia, visual analog scale pain score, and side effects were compared between these groups. Results: Two-segment regression time of sensory blockade and duration of effective analgesia were prolonged in both Group C (1.2 mg nalbuphine) and Group D (1.6 mg nalbuphine) compared to Groups A and B (P < 0.05), but the incidence of side effects was significantly higher in Group D (P < 0.05). Conclusion: Nalbuphine 1.2 mg is the optimum intrathecal dose which prolongs postoperative analgesia without increased side effects.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1394    
    Printed34    
    Emailed0    
    PDF Downloaded146    
    Comments [Add]    

Recommend this journal